Why Did Sharon Osbourne Have a Double Mastectomy?

It’s been a year of high and lows for America’s Got Talent judge and The Talk co-host Sharon Osbourne.

Sharon and Ozzy celebrated their 30th wedding anniversary, her son Jack got married, and he and wife Lisa Stelly just gave Sharon her first grandchild- Pearl.

But Jack was also diagnosed with multiple sclerosis in June, and she quit America’s Got Talent after because she was not happy about the way NBC cancelled Jack’s appearance on a reality show after his diagnosis.

And now Sharon has revealed that she underwent a bilateral mastectomy last summer when she found out that she carries the breast cancer gene.

Sharon and Ozzy both had their genomes analyzed, and while Ozzy’s came up clean, hers revealed that she had both the colon cancer gene (which she was diagnosed with 10 years ago) as well as the breast cancer gene.

In an interview in this week’s British magazine Hello! Sharon talks honestly about why she underwent the procedure:

As soon as I found out I had the breast cancer gene, I thought: ‘The odds are not in my favour.’ I’ve had cancer before and I didn’t want to live under that cloud: I decided to just take everything off, and had a double mastectomy.

For me, it wasn’t a big decision, it was a no-brainer. I didn’t want to live the rest of my life with that shadow hanging over me. I want to be around for a long time and be a grandmother to Pearl.

Sharon also revealed that another factor in her decision was that one of her breast implants was leaking into the wall of her stomach. She also underwent reconstructive surgery during the 13-hour long mastectomy procedure:

They’re very small now…[but] I’m happy with them… I just wanted to be cancer-free.

What You Need to Know About Breast Cancer Genes (BRCA1 and BRCA2)

1.  BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor suppressors. In normal cells, BRCA1 and BRCA2 help ensure the stability of the cell’s genetic material (DNA) and help prevent uncontrolled cell growth. Mutation of these genes has been linked to the development of hereditary breast and ovarian cancer.

2.  Not all gene changes, or mutations, are deleterious (harmful). Some mutations may be beneficial, whereas others may have no obvious effect. Harmful mutations can increase a person’s risk of developing a disease, such as cancer.

3.  A woman’s lifetime risk of developing breast and/or ovarian cancer is greatly increased if she inherits a harmful mutation in BRCA1 or BRCA2. Such a woman has an increased risk of developing breast and/or ovarian cancer at an early age (before menopause) and often has multiple, close family members who have been diagnosed with these diseases.

4.  The likelihood that a breast and/or ovarian cancer is associated with a harmful mutation in BRCA1 or BRCA2 is highest with a family history of several members with breast and/or ovarian cancer.

5.  But not every woman in such families carries a harmful BRCA1 or BRCA2 mutation, and not every cancer in such families is linked to a harmful mutation in one of these genes. Not every woman who has a harmful BRCA1 or BRCA2 mutation will develop breast and/or ovarian cancer.

6.  According to estimates of lifetime risk, about 12.0 % of women (120 out of 1,000) in the general population will develop breast cancer sometime during their lives compared with about 60 percent of women (600 out of 1,000) who have inherited a harmful mutation in BRCA1 or BRCA2. In other words, a woman who has inherited a harmful mutation in BRCA1 or BRCA2 is about five times more likely to develop breast cancer than a woman who does not have such a mutation.

7.  Lifetime risk estimates for ovarian cancer among women in the general population indicate that 1.4 %(14 out of 1,000) will be diagnosed with ovarian cancer compared with 15 to 40 % of women (150–400 out of 1,000) who have a harmful BRCA1 or BRCA2 mutation.

8.  There are three specific mutations, two in the BRCA1 gene and one in the BRCA2 gene, that are the most common mutations found in the Ashkenazi Jewish population (those of Eastern European descent).

9.  Several methods are available to test for BRCA1 and BRCA2 mutations. Most of these methods look for changes in BRCA1 and BRCA2 DNA. A blood sample is needed for these tests

10.  Currently, there are no standard criteria for recommending or referring someone for BRCA1 or BRCA2 mutation testing.

11.  In a family with a history of breast and/or ovarian cancer, it may be most useful to test a family member who has breast or ovarian cancer first. If that person is found to have a BRCA1 or BRCA2 mutation, then other family members can be tested to see if they also have the mutation.

12.  A positive test result generally indicates that a person has inherited a known harmful mutation in BRCA1 or BRCA2 and, therefore, has an increased risk of developing certain cancers. However, a positive test result provides information only about a person’s risk of developing cancer. It cannot tell whether an individual will actually develop cancer or when. Not all women who inherit a harmful BRCA1 or BRCA2 mutation will develop breast or ovarian cancer.

13.   Having a negative test result does not mean that a person will not develop cancer; it means that the person’s risk of cancer is probably the same as that of people in the general population.

14.  Several options are available for managing cancer risk in individuals who have a harmful BRCA1 or BRCA2 mutation.

  • Surveillance—Surveillance means cancer screening, or a way of detecting the disease early. Screening does not, however, change the risk of developing cancer. The goal is to find cancer early, when it may be most treatable. Mammography and clinical breast exams may be performed every 6 months.
  • Prophylactic Surgery—This type of surgery involves removing as much of the “at-risk” tissue as possible in order to reduce the chance of developing cancer. It greatly reduces but can not completely eliminate the risk of developing cancer.
  • Chemoprevention—This approach involves the use of natural or synthetic substances to reduce the risk of developing cancer. For example, the drug tamoxifen has been shown in numerous clinical studies to reduce the risk of developing breast cancer by about 50 percent in women who are at increased risk of this disease.
Michele R. Berman, M.D. was Clinical Director of The Pediatric Center, a private practice on Capitol Hill in Washington, D.C. from 1988-2000, and was named Outstanding Washington Physician by Washingtonian Magazine in 1999. She was a medical internet pioneer having established one of the first medical practice websites in 1997. Dr. Berman also authored a monthly column for Washington Parent Magazine.

3 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Real Time Analytics Google Analytics Alternative